Altered expression of transforming growth factor-β ligands and receptors in primary and recurrent ovarian carcinoma

Cancer

Volumn 85, Issue 3, 1999, Pages 658-668

  Bristow, Robert E ^a   Baldwin, Rae Lynn ^a   Yamada, S Diane ^a,c   Korc, Murray ^b   Karlan, Beth Y ^a,d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

Iigand; Ovarian carcinoma; Receptor; Transforming growth factor

Indexed keywords

TRANSFORMING GROWTH FACTOR BETA RECEPTOR; TRANSFORMING GROWTH FACTOR BETA1; TRANSFORMING GROWTH FACTOR BETA3;

ARTICLE; CANCER RECURRENCE; CARCINOGENESIS; CONTROLLED STUDY; DIAGNOSTIC VALUE; FEMALE; GROWTH INHIBITION; HUMAN; HUMAN TISSUE; OVARY CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION;

BLOTTING, NORTHERN; BLOTTING, SOUTHERN; CYSTADENOCARCINOMA, PAPILLARY; FEMALE; HUMANS; LIGANDS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; OVARIAN NEOPLASMS; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; RNA, MESSENGER; TRANSFORMING GROWTH FACTOR BETA;

EID: 0033082311     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19990201)85:3<658::AID-CNCR16>3.0.CO;2-M     Document Type: Article

References (56)

1. Massague J, Cheifatz S, Laiho M, Ralph DA, Weis FM, Zentella A. Transforming growth factor β. Cancer Surv 1992;12: 81-103.
2. Sporn MB, Roberts AB. Transforming growth factor-β: recent progress and new challenges. J Cell Biol 1992;119:1017-21.
3. Moses HL, Yang EY, Pientenpol JA. TGF-β1 stimulation and inhibition of cell proliferation: new mechanistic insights. Cell 1990;63:245-7.
4. Schwarz LC, Wright JA, Gingras M-C, Konaiah P, Danielpour D, Pimentel M, et al. Aberrant TGF-β production and regulation in metastatic malignancy. Growth Factors 1990;3:115-27.
5. Sorrentino V, Bandyopadhyay S. TGF-β inhibits G1/S-phase transition in primary fibroblasts: loss of response to the antigrowth effect of TGF-β is observed after immortalization. Oncogene 1989;4:569-74.
6. Beauchamp RD, Lyons RM, Yang EY, Coffey RJ Jr., Moses HL. Expression of and response to growth regulatory peptides by two human pancreatic carcinoma cell lines. Pancreas 1990;5:369-80.
7. Ito M, Yasui W, Kyo E, Yokozaki H, Nakayama H, Ito H, et al. Growth inhibition of transforming growth factor β on human gastric carcinoma cells: receptor and postreceptor signaling. Cancer Res 1992;52:295-300.
8. Laiho M, DeCaprio JA, Ludlow JW, Livingston DM, Massague J. Growth inhibition by TGF-β linked to suppression of retinoblastoma protein phosphorylation. Cell 1990;62: 175-85.
9. Gerwin BI, Spillare EI, Forrester K, Lehamn TA, Kispert J, Welsh JA, et al. Mutant p53 can induce tumorigenic conversion of human bronchial epithelial cells and reduce their responsiveness to a negative growth factor, transforming growth factor β1. Proc Natl Acad Sci USA 1992;89:2759-63.
10. Baldwin RL, Korc M. Growth inhibition of human pancreatic carcinoma cells by transforming growth factor beta-1. Growth Factors 1993;8:23-34.
11. Friess H, Yamanaka Y, Buchler M, Ebert M, Beger HG, Gold LI, et al. Enhanced expression of transforming growth factor β isoforms in pancreatic cancer correlates with decreased survival. Gastroenterology 1993;105:1846-56.
12. Gomella LG, Sargent ER, Wade TP, Anglard P, Linehan WM, Kasid A. Expression of transforming growth factor a in normal human adult kidney and enhanced expression of transforming growth factors α and β1 in renal cell carcinoma. Cancer Res 1989;49:6972-5.
13. Ito N, Kawata S, Tamura S, Takaishi K, Shirai Y, Kiso S, et al. Elevated levels of transforming growth factor β messenger RNA and its polypeptide in human hepatocellular carcinoma. Cancer Res 1989;51:4080-3.
14. Niitsu Y, Urushizaki Y, Koshida Y, Terui K, Mahara K, Kohgo Y, et al. Expression of TGF-β gene in adult T cell leukemia. Blood 1988;71:263-6.
15. Travers MT, Barrett-Lee PJ, Berger U, Luqmani YA, Gazet J-C, Powers TJ, et al. Growth factor expression in normal, benign, and malignant breast tissue. BMJ 1988;296:1621-4.
16. Steiner MS, Barrack ER. Transforming growth factor-β1 overproduction in prostate cancer: effects on growth in vivo and in vitro. Mol Endocrinol 1992;6:15-25.
17. Anzano MA, Roberts AB, DeLarco JE, Wakefield LM, Assoian RK, Roche NS, et al. Increased secretion of type beta transforming growth factor accompanies viral transformation of cells. Mol Cell Biol 1985;5:242-7.
18. Ferriola PC, Walker C, Robertson AT, Earp HS, Rusnak DW, Nettesheim R. Altered growth factor dependence and transforming factor gene expression in transformed rat tracheal epithelial cells. Mol Carcinog 1989;2:336-44.
19. Jennings MT, Maciunas RJ, Carver R, Bascom CC, Juneau P, Misulis K, et al. TGF-β1 and TGF-β2 are potent growth regulators for low-grade and malignant gliomas in vitro: evidence in support of an autocrine hypothesis. Int J Cancer 1991;49:129-39.
20. Knabbe C, Lippman ME, Wakefield LM, Flanders KC, Kasid A, Derynck R, et al. Evidence that transforming growth factor-β is a hormonally regulated negative growth factor in human breast cancer cells. Cell 1987;48:417-28.
21. Liu C, Tsao MS, Grisham JW. Transforming growth factors produced by normal and neoplastically transformed rat liver epithelial cells in culture. Cancer Res 1988;48:850-5.
22. Arrick BA, Lopez AR, Elfman F, Ebner R, Damsky CH, Derynck R. Altered metabolic and adhesive properties and increased tumorigenesis associated with increased expression of transforming growth factor β1. J Cell Biol 1988;118: 715-26.
23. Chang H-L, Gillett N, Figari I, Lopez AR, Palladino MA, Derynck R. Increased transforming growth factor β expression inhibits cell proliferation in vitro, yet increases tumorigenicity and tumor growth of Meth A sarcoma cells. Cancer Res 1993;53:4391-8.
24. Hurteau J, Rodriguez GC, Whitaker RS, Shah S, Mills G, Bast R, et al. Transforming growth factor-β inhibits proliferation of human ovarian cancer cells obtained from ascites. Cancer 1994;74:93-9.
25. Berchuck A, Rodriguez G, Olt G, Whitaker R, Boente MP, Arrick BA, et al. Regulation of growth of normal ovarian epithelial cells and ovarian cancer cell lines by transforming growth factor-β. Am J Obstet Gynecol 1992;166:676-84.
26. Henriksen R, Gobl A, Wilander E, Oberg K, Miyazono K, Funa K. Expression and prognostic significance of TGF-β isotypes, latent TGF-β1 binding protein, TGF-β type I and type II receptors, and endoglin in normal ovary and ovarian neoplasms. Lab Invest 199573:213-20.
27. Massague J. Receptors for the TGF-β family. Cell 1992;69: 1067-70.
28. tenDijke P, Yamashita H, Icjijo H, Franzen P, Laiho M, Miyazono K, et al. Characterization of type I receptors for transforming growth factor beta and activin. Science 1994; 264:101-4.
29. Lin HY, Wang X-F, Ng-Eaton E, Weinberg RA, Lodish HF. Expression cloning of the TGF-β type II receptor, a functional transmembrane serine/threonine kinase. Cell 1992; 68:775-85.
30. Wrana JL, Attisano L, Carcamo J, Zentella A, Doody J, Laiho M, et al. TGF-β signals through a heteromeric protein kinase receptor complex. Cell 1992;71:1003-14.
31. Franzen P, ten Dijke P, Ichijo H, Yamashita H, Schulz P, Heldin C-H, et al. Cloning of a TGFβ type I receptor that forms a heteromeric complex with the TGFβ type II receptor. Cell 1993;75:681-92.
32. Wrana J, Attisano L, Weiser R, Ventura F, Massague T. Mechanisms of activation of the TGF-β receptor. Nature 1994;370: 341-7.
33. Yamashita H, ten Dijke P, Franzen P, Miyazono K, Heldin C-H. Formation of hetero-oligomeric complexes of type I and type II receptors for transforming growth factor β. J Biol Chem 1994;269:20172-8.
34. Inagaki M, Mousta A, Lin HY, Lodish HF, Carr BI. Growth inhibition by transforming growth factor β (TGF-β1) type I is restored in TGF-β-resistant hepatoma cells after expression of TGF-β receptor type II cDNA. Proc Natl Acad Sci USA 1993;90:5359-63.
35. Sun L, Wu G, Willson JK, Zborowski E, Yang J, Rajkarunanayake I, et al. Expression of transforming growth factor β type II receptor leads to reduced malignancy in human MCF-7 cells. J Biol Chem 1994;269:26449-55.
36. Ito M, Yasui W, Nakayama H, Yokozaki H, Ito H, Tahara E. Reduced levels of transforming growth factor-beta type I receptor in human gastric carcinomas. Jpn J Cancer Res 1992;83:86-92.
37. Kim IY, Ahn A-H, Zelner DJ, Shaw JW, Sensibar JA, Kim J-H, et al. Genetic change in transforming growth factor β (TGF-β) receptor type I gene correlates with insensitivity to TGF-β1 in human prostate cancer cells. Cancer Res 1996;56: 44-8.
38. Wang X-F, Lin HY, Ng-Eaton E, Downward J, Lodish HF, Weinberg RA. Expression cloning and characterization of the TGF-β type III receptor. Cell 1991;67:797-805.
39. Lopez-Casillas F, Wrana JL, Massague J. Betaglycan presents ligand to the TGF-β signaling receptor. Cell 1993; 73:1435-44.
40. Arrick BA, Korc M, Derynck R. Differential regulation of expression of three transforming growth factor-β species in human breast cancer cell lines by estradiol. Cancer Res 1990;50:299-303.
41. Friess H, Yamanaka H, Buchler M, Beger HG, Kobrin MS, Baldwin RL, et al. Enhanced expression of the type II transforming growth factor-β receptor in human pancreatic cancer cells without alteration of type III receptor expression. Cancer Res 1993;53:2704-7.
42. Baldwin RL, Friess H, Yokoyama M, Lopez ME, Kobrin MS, Buchler MW, et al. Attenuated ALK5 receptor expression in human pancreatic cancer: correlation with resistance to growth inhibition. Int J Cancer 1996;67:283-8.
43. Chomzynski P, Sacchi N. Single-step RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987;162:156-9.
44. Shimizu S, Nishikawa Y, Kuroda K, Takagi S, Kozaki K, Hyuga S, et al. Involvement of transforming growth factor β1 in autocrine enhancement of gelatinase B secretion by murine metastatic colon carcinoma cells. Cancer Res 1990;56: 3366-70.
45. Welch DR, Fabra A, Nakajima M. Transforming growth factor β stimulates mammary adenocarcinoma cell invasion and metastatic potential. Proc Natl Acad Sci USA 1990;87: 7678-82.
46. Monteagudo R, Merino M, San-Juan J, Liotta LA, Stetler-Stevenson WG. Immunohistochemical distribution of type IV collagenase in normal, benign, and malignant breast tissue. Am J Pathol 1990;136:585-92.
47. r 72,000 type IV collagenase in human colonic adenocarcinoma. Cancer Res 1991;51:439-44.
48. Campo E, Merino MJ, Liotta L, Neumann R, Stetler-Stevenson WG. Distribution of the 72-kd type IV collagenase in nonneoplastic and neoplastic thyroid tissue. Hum Pathol 1992;23:1395-401.
49. Brown PD, Bloxidge RE, Stuart NSA, Gatter KC, Carmichael J. Association between expression of activated 72-kilodalton gelatinase and tumor spread in non-small-cell lung carcinoma. J Natl Cancer Inst 1993;85:574-8.
50. Stearns ME, Wang M. Type IV collagenase (Mr 72,000) expression in human prostate: benign and malignant tissue. Cancer Res 1993;53:878-83.
51. r 92,000 type IV collagenase in human brain tumors. Cancer Res 1993;53: 2208-11.
52. Shull MM, Ormsby I, Kier AB, Pawlowski S, Diebold RJ, Yin M, et al. Targeted disruption of the mouse transforming growth factor-β1 gene results in multifocal inflammatory disease. Nature 1992;359:693-9.
53. Myerhoff LL, Parsons R, Kim S-J, Hedrick L, Cho KR, Orgh K, et al. A transforming growth factor β receptor type II gene mutation common in colon and gastric but rare in endometrial cancers with microsatellite instability. Cancer Res 1995; 55:5545-7.
54. Markowitz S, Wang J, Myeroff L, Parsons R, Sun L, Luttergaugh J, et al. Inactivation of the type II TGF-β receptor in colon cancer cells with microsatellite instability. Science 1995;268:1336-8.
55. Iwabuchi HY, Sakamoto M, Sakunaga H, Ma Y-Y, Carcangiu ML, Pinkel D, et al. Genetic analysis of benign, low-grade, and high-grade ovarian tumors. Cancer Res 1995;55:6172-80.
56. Tangir J, Loughridge NS, Berkowitz TS, Muto MG, Bell DA, Welch WR, et al. Frequent microsatellite instability in epithelial borderline ovarian tumors. Cancer Res 1996;56: 2501-5.